Institutional shares held 98.3 Million
784K calls
713K puts
Total value of holdings $1.19B
$9.51M calls
$8.65M puts
Market Cap $922M
76,011,800 Shares Out.
Institutional ownership 129.36%
# of Institutions 340


Latest Institutional Activity in NTLA

Top Purchases

Q2 2025
Versant Capital Management, Inc Shares Held: 1.7K ($20.6K)
Q2 2025
Parallel Advisors, LLC Shares Held: 618 ($7.5K)
Q1 2025
Capital International Investors Shares Held: 3.78M ($45.8M)
Q1 2025
Contrarius Group Holdings LTD Shares Held: 2.02M ($24.5M)
Q1 2025
Vanguard Group Inc Shares Held: 10.8M ($130M)

Top Sells

Q2 2025
Farther Finance Advisors, LLC Shares Held: 83 ($1.01K)
Q2 2025
Massmutual Trust CO Fsb Shares Held: 99 ($1.2K)
Q1 2025
Balyasny Asset Management LLC Shares Held: 1.52M ($18.4M)
Q1 2025
State Street Corp Shares Held: 4.51M ($54.7M)
Q1 2025
Ubs Group Ag Shares Held: 1.13M ($13.7M)

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at NTLA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
487K Shares
From 17 Insiders
Grant, award, or other acquisition 472K shares
Exercise of conversion of derivative security 14.5K shares
Sell / Disposition
80.7K Shares
From 9 Insiders
Open market or private sale 80.7K shares

Track Institutional and Insider Activities on NTLA

Follow Intellia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA